What is FENC's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.38B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for FENC?

P/E (TTM) is n/a and 52-week range is $5.65 to $13.25 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s FENC figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for FENC?

The company profile lists revenue (TTM) near $56M, net income (TTM) near $-310M, EPS (TTM) near $-0.12 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Fennec Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Research Triangle Park, North Carolina, US, 34.7M shares outstanding, ISIN CA31447P1009 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Fennec Pharmaceuticals Inc

$FENC

Health Care · Biotechnology

IR Run Scenarios

$10.71

+0.75%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

Employees

Website

fennecpharma.com/

IPO

2001-06-05

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)